NV-NTT
13.5.2020 10:44:08 CEST | Business Wire | Press release
The city of Las Vegas and NTT Corporation (NTT) today announced the Accelerate Smart project has expanded to include two new locations – the city’s Community Healing Garden and a portion of Las Vegas Boulevard at South Main Street and East St. Louis Avenue. As part of the partnership, NTT and the city plan to further expand the smart cities project to Bob Baskin Park, Rotary Park, Stupak Park and Ethel Pearson Park this summer before adding six additional parks by the end of 2020.
Following the success of the initial pilot , which has improved traffic congestion and wrong way driving, NTT will expand the project to provide real-time alerts of safety conditions and maintenance issues to improve public safety and provide a better experience for citizens and visitors. The city’s Smart Park Initiative is designed to increase public safety, while providing awareness of activity to generate usage and operations benchmarks that allow leadership to make more informed decisions.
In total, high-definition optical and audio sensors will now be deployed at 14 locations across the city, which enable an automated system to notify law enforcement and maintenance personnel of safety hazards, such as large crowds, gunshots, breaking glass and vandalism.
“Cities that learn, understand and invest in technology will be the cities of the future, and Las Vegas is at the forefront of innovation,” said Michael Sherwood, Director of Innovation and Technology, city of Las Vegas. “Our Smart Cities pilot has been such a success that we are excited to expand the program to several new locations in the heart of our city, which will continue to improve the lives of our residents and visitors.”
The initial proof of concept provided information to city personnel to increase situational awareness and provide a foundation for traffic management. With the expansion of the smart cities project, Las Vegas will leverage a dashboard to access and view sensors, data streams and analytics. The timely alerts and predictions enable the city to monitor and review events and allow them to dispatch safety and maintenance personnel in a timely manner.
The NTT Accelerate Smart data platform is a secure, distributed platform that captures data via sensors and micro data centers in the designated areas through video and sound, while also integrating historical data sources such as crime, weather and social media. By leveraging cognitive analytics, including machine learning technologies, the system learns normal patterns and can detect and alert authorities of patterns that appear abnormal.
“As we accelerate our smart cities project in Las Vegas, it demonstrates how a more connected society directly benefits citizens,” said Bill Baver, Go to Market Leader, Smart World Team, NTT. “Cities like Las Vegas are capitalizing on successful pilots and beginning to imagine the benefits these technologies can have for their residents and visitors. However, smart is not confined to city limits, as it also extends to stadiums, shopping malls and manufacturing facilities by leveraging similar concepts that have been proven successful in Las Vegas.”
The Accelerate Smart solution deployed in Las Vegas is built on NTT’s innovative Cognitive Foundation™ architecture, which enables remote creation, management and operation of information and communications technology resources, from devices and networks to the cloud. It also incorporates hyperconverged infrastructure and IoT gateways, as well as virtualization software hosting predictive analytics applications.
The partnership with NTT is part of the city of Las Vegas’ charter in becoming a smart city to provide safe, reliable and efficient civic technology that stimulates economic growth. To learn more about the Smart Cities initiative in Las Vegas, visit NTT’s website and watch the case study on YouTube .
About NTT
NTT believes in resolving social issues through our business operations by applying technology for good. We help clients accelerate growth and innovate for current and new business models. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks all supported by our deep industry expertise and innovation.
As a top 5 global technology and business solutions provider, our diverse teams operate in 88 countries and regions and deliver services to over 190 of them. We serve 85% of Fortune Global 100 companies and thousands of other clients and communities around the world.
For more information on NTT, visit www.global.ntt/
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005261/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom